Cyclacel Pharmaceuticals (CYCC) Insider Trading & Ownership $0.24 -0.01 (-5.31%) Closing price 04:00 PM EasternExtended Trading$0.25 +0.01 (+2.25%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cyclacel Pharmaceuticals (NASDAQ:CYCC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage68.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$5.84 M Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYCC Insider Buying and Selling by Quarter Cyclacel Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/26/2025David E. LazarCEOSell194,628,820$0.03$5,838,864.60 (Data available from 1/1/2013 forward) CYCC Insider Trading Activity - Frequently Asked Questions Who is on Cyclacel Pharmaceuticals's Insider Roster? The list of insiders at Cyclacel Pharmaceuticals includes David E. Lazar, Paul Mcbarron, and Spiro George Rombotis. Learn more on insiders at CYCC. What percentage of Cyclacel Pharmaceuticals stock is owned by insiders? 68.00% of Cyclacel Pharmaceuticals stock is owned by insiders. Learn more on CYCC's insider holdings. Which Cyclacel Pharmaceuticals insiders have been buying company stock? The following insiders have purchased CYCC shares in the last 24 months: Paul Mcbarron ($6,242.66), and Spiro George Rombotis ($20,091.70). How much insider buying is happening at Cyclacel Pharmaceuticals? Insiders have purchased a total of 7,956 CYCC shares in the last 24 months for a total of $26,334.36 bought. Which Cyclacel Pharmaceuticals insiders have been selling company stock? The following insider sold CYCC shares in the last 24 months: David E. Lazar ($5,838,864.60). How much insider selling is happening at Cyclacel Pharmaceuticals? Insiders have sold a total of 194,628,820 Cyclacel Pharmaceuticals shares in the last 24 months for a total of $5,838,864.60 sold. Cyclacel Pharmaceuticals Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Compensation: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Compensation: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Compensation: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations Executive More Insider Trading Tools from MarketBeat Related Companies Tevogen Bio Insider Trading Kodiak Sciences Insider Trading Canopy Growth Insider Trading Esperion Therapeutics Insider Trading INmune Bio Insider Trading Inhibrx Insider Trading Actuate Therapeutics Insider Trading LifeVantage Insider Trading Aardvark Therapeutics Insider Trading DiaMedica Therapeutics Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:CYCC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCC Stock Free CYCC Stock Alerts